Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.
COVID-19
Convalescent plasma
Outcome
SARS-CoV-2
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
03
06
2024
accepted:
20
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19. This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients. A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P<0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P <0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients. Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.
Identifiants
pubmed: 39350163
doi: 10.1186/s12985-024-02475-y
pii: 10.1186/s12985-024-02475-y
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
239Subventions
Organisme : Ministerstvo Obrany České Republiky
ID : MO1012
Organisme : Ministerstvo Obrany České Republiky
ID : MO1012
Informations de copyright
© 2024. The Author(s).
Références
Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol. 2004;11:665–8. https://doi.org/10.1128/CDLI.11.4.665-668.2004
doi: 10.1128/CDLI.11.4.665-668.2004
pubmed: 15242938
pmcid: 440610
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–6. https://doi.org/10.1007/s10096-004-1271-9
doi: 10.1007/s10096-004-1271-9
pubmed: 15616839
Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–22. https://doi.org/10.1093/jac/dki346
doi: 10.1093/jac/dki346
pubmed: 16183666
Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77:147–50. https://doi.org/10.1002/jmv.20431
doi: 10.1002/jmv.20431
pubmed: 16121363
pmcid: 7167078
Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using Convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22:1554–61. https://doi.org/10.3201/eid2209.151164
doi: 10.3201/eid2209.151164
pubmed: 27532807
pmcid: 4994343
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. https://doi.org/10.1093/infdis/jiu396
doi: 10.1093/infdis/jiu396
pubmed: 25030060
Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23:39–44. https://doi.org/10.1016/j.tracli.2015.12.003
doi: 10.1016/j.tracli.2015.12.003
pubmed: 26775794
pmcid: 7110444
Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695–03. https://doi.org/10.1038/nrmicro974
doi: 10.1038/nrmicro974
pubmed: 15372080
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–09. https://doi.org/10.7326/0003-4819-145-8-200610170-00139
doi: 10.7326/0003-4819-145-8-200610170-00139
pubmed: 16940336
Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–56. https://doi.org/10.1093/cid/ciq106
doi: 10.1093/cid/ciq106
pubmed: 21248066
World Health Organisation. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks, WHO Interim Guidance for National Health Authorities and Blood Transfusion Services, Version 1.0. September 2014, WHO/HIS/SDS/2014.8. https://apps.who.int/iris/handle/10665/135591 ; 2014 [accessed 3 April 2024].
Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect. 2017;74(3):302–9. https://doi.org/10.1016/j.jinf.2016.11.009
doi: 10.1016/j.jinf.2016.11.009
pubmed: 27867062
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES et al. Effect of Convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-Month experience. Effect of Convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-Month experience | medRxiv; 2020 [accessed 12 April 2024].
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384:610–8. https://doi.org/10.1056/NEJMoa2033700
doi: 10.1056/NEJMoa2033700
pubmed: 33406353
An EU. programme of COVID-19 convalescent plasma collection and transfusion. https://health.ec.europa.eu/document/download/04a77c82-906e-4840-bc35-0faaccd33f02_en ; 2020 [accessed 12 April 2024].
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A Randomized Trial of Convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–29. https://doi.org/10.1056/NEJMoa2031304
doi: 10.1056/NEJMoa2031304
pubmed: 33232588
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [published correction appears in BMJ. 2020;371:m4232]. BMJ 2020;371:m3939. https://doi.org/10.1136/bmj.m3939
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–59. https://doi.org/10.1016/S0140-6736(21)00897-7
doi: 10.1016/S0140-6736(21)00897-7
Bohoněk M, Bělochová J, Čermáková Z, Dušková D, Gašová Z, Galuszková D, et al. Výroba a použití rekonvalescentní plazmy anti-SARS-CoV-2 v ČR: stručná informace. Trans Hematol dnes. 2021;27(2):189–90.
FDA Issues Emergency Use Authorization for Convalescent. Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment ; 2020 [accessed 12 April 2024].
Černý V, Bohoněk M, Dlouhý P, Vašáková M. Mezioborové stanovisko k podávání rekonvalescentní plazmy u pacientů s COVID-19, ev. č. ČSARIM: 18/2021, 2.3.2021. https://www.csarim.cz/getmedia/0d4a80ec-41de-459b-aa2c-1f6a2f1042a5/2021_PP_18_CSARIM_STL_SIL_CPFS_Rekonv_plazma_final_020321.pdf.aspx ; 2020 [accessed 12 April 2024].
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–26. https://doi.org/10.1056/NEJMoa2007764
doi: 10.1056/NEJMoa2007764
pubmed: 32445440
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.
doi: 10.1503/cmaj.050051
pubmed: 16129869
pmcid: 1188185
Bohoněk M, Řezáč D, Kutáč D, Vabroušek P, Kubů J, Jakub T, et al. Report on the program of the use of convalescent plasma in the treatment of patients with COVID-19 in the Czech Republic and the results of the national multicentre study RESCOVID-19. Trans Hematol dnes. 2023;29:193–9.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–70. https://doi.org/10.1001/jama.2020.10044
doi: 10.1001/jama.2020.10044
pubmed: 32492084
Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136:759–62. https://doi.org/10.1182/blood.2020006964
doi: 10.1182/blood.2020006964
pubmed: 32559767
Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and Meta-analysis. JAMA Netw Open. 2023;6:e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647
doi: 10.1001/jamanetworkopen.2022.50647
pubmed: 36633846
pmcid: 9857047
Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VCC, Edwards KM et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2022 Sep 5:ciac724. https://doi.org/10.1093/cid/ciac724
FDA announces Evusheld is not currently authorized for emergency use in the U.S. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:~:text=Update%20%5B1%2F26%2F2023,than%20or%20equal%20to%2090%2 ; 2023 [accessed 12 April 2024].
Martinuka O, von Cube M, Wolkewitz M. Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness. Clin Microbiol Infect. 2021;27:949–57. https://doi.org/10.1016/j.cmi.2021.03.003
doi: 10.1016/j.cmi.2021.03.003
pubmed: 33813117
pmcid: 8015394